11:15 AM - 11:30 AM (EST), Tuesday, February 7, 2023 ・ Winter Garden
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Eupraxia's lead product candidate, EP-104, is currently in Phase 2 development for the treatment of pain